BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 11, 2009
 |  BioCentury  |  Strategy

Acadia Rising

A deal for pimavanserin last week may put the wind back in the sails of Acadia Pharmaceuticals Inc. while it looks to grow its portfolio through in-licensing late-stage or marketed specialty CNS drugs.

Biovail Corp. paid $30 million up front for U.S. and Canadian rights to the small molecule serotonin (5-HTA) receptor inverse agonist, which is in Phase III testing for Parkinson's disease psychosis. Acadia is eligible for up to $365 million in milestones, plus a 15-20% royalty.

According to Acadia President and CEO Uli Hacksell, there are no approved drugs for PDP. "Some marketed anti-psychotics are used off label for PDP, but in order for them to be tolerated by patients, they have to be used at lower doses, where their efficacy is minimal at best," he told BioCentury.

Hacksell noted that marketed anti-psychotics include a black box warning against their use in elderly patients with dementia-related psychosis, while pimavanserin has been well-tolerated in its clinical development.

Hacksell estimated 40% of the 1.5 million PD patients in the U.S. suffer from the...

Read the full 852 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >